AB Science Receives EMA Update on Masitinib ALS Marketing Authorization Application

AB Science has received an update from the European Medicines Agency (EMA) regarding the marketing authorization application for masitinib for the treatment of amyotrophic lateral sclerosis (ALS). The pharmaceutical company awaits further assessment.

Masitinib is an orally administered, small molecule tyrosine kinase inhibitor developed by AB Science. The drug's efficacy and safety in ALS patients have been investigated through clinical studies.

ALS is a progressive neurodegenerative disease that affects nerve cells in the spinal cord and brain, leading to muscle weakness and eventual respiratory failure. Currently, there is no cure for ALS, and existing treatments aim to slow disease progression and manage symptoms.

AB Science continues to engage with the EMA to ensure the review process is followed and awaits further information on the progression of the evaluation. The company did not provide specific details about the nature or timeline of the update.